Market news

Under the terms of the Amendment, all disputed issues are resolvedSAN DIEGO and NERVIANO, Italy, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ: CRDF) ("Cardiff") and Nerviano Medical Sciences S.r.l. ("NMS") today announced that they have reached a settlement and amended their 2017 Exclusive License Agreement, resolving all outstanding disputes between the two companies related to the global rights for onvansertib, Cardiff's lead PLK1 inhibitor drug candidate, and establishing

2026-09-10. The following slide deck was published by Cardiff Oncology, Inc.

SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that Mani Mohindru, Ph.D. will participate in two upcoming conferences. Details of the company’s participation are as follows: 8th Annual RAS-Targeted Drug Development Summit Advancing PLK1 Targeted Therapy to Transform Outcomes in RAS Mutant Metastatic Colorectal Cancer; Tuesda

Detailed price information for Neurogene Inc (NGNE-Q) from The Globe and Mail including charting and trades.

Detailed price information for Cardiff Oncology Inc (CRDF-Q) from The Globe and Mail including charting and trades.

Cardiff Oncology (CRDF) has an average rating of overweight and mean price target of $6.21, accordin

Positive Phase 2 CRDF-004 data presented in an oral session at ASCO support advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into planned registrational program for first-line RAS-mutated mCRC Following successful End-of-Phase 2 meeting with FDA, Company aligned on key elements of registrational trial; plans to initiate study in Q1 2027, subject to securing additional financing Completed $10 million Registered Direct offering, extending cash runway SAN DIEGO, Aug. 11, 2026 (GLOBE NEWSWI

Cardiff Oncology: Q2 Earnings Snapshot

SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF) (the “Company”), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 8,571,429 shares of its common stock and accompanying warrants to purchase up to an aggregate of 8,571,429 shares of its common stock, at a purchase price of $1.05 per share and accompanying

Cardiff Oncology has secured a $10 million registered direct offering, providing additional capital for working capital and general corporate purposes as the company continues advancing its lead oncology program. Key Investor TakeawaysCardiff Oncology (NASDAQ:CRDF) expects to raise approximately $10 million in gross proceeds through a registered direct offering.